Michael L Friedlander

36PUBLICATIONS
375CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Jul 10, 2026
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

|Jul 06, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

|Apr 01, 2026
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey

|Jan 14, 2026
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.

Mahendra Naidoo, Orla McNally, Clare L Scott

|Nov 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Dale Garsed, Tibor Zwimpfer, Sian Fereday

|Nov 05, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound

Pageof 6

Frequent Collaborators

7 joint publications

Kelly-Anne Phillips

6 joint publications

Paul Cohen

6 joint publications

Roger Milne

6 joint publications

Anna DeFazio